Lineage Cell Therapeutics Statistics
Share Statistics
Lineage Cell Therapeutics has 220.42M shares outstanding. The number of shares has increased by 7.91% in one year.
| Shares Outstanding | 220.42M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 218.96M |
| Failed to Deliver (FTD) Shares | 20 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 15.94M, so 8.44% of the outstanding shares have been sold short.
| Short Interest | 15.94M |
| Short % of Shares Out | 8.44% |
| Short % of Float | 8.48% |
| Short Ratio (days to cover) | 35.21 |
Valuation Ratios
The PE ratio is -8.76 and the forward PE ratio is -6.33.
| PE Ratio | -8.76 |
| Forward PE | -6.33 |
| PS Ratio | 21.04 |
| Forward PS | 13.3 |
| PB Ratio | 2.97 |
| P/FCF Ratio | -6.44 |
| PEG Ratio | n/a |
Enterprise Valuation
Lineage Cell Therapeutics Inc. has an Enterprise Value (EV) of 155.71M.
| EV / Earnings | -7.25 |
| EV / Sales | 17.41 |
| EV / EBITDA | -6.48 |
| EV / EBIT | -6.3 |
| EV / FCF | -5.33 |
Financial Position
The company has a current ratio of 2.14, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.14 |
| Quick Ratio | 2.14 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.37 |
| Cash Flow / Debt | -32.39 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -35.12%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.21% |
| Return on Capital (ROIC) | -35.12% |
| Revenue Per Employee | 131.54K |
| Profits Per Employee | -315.97K |
| Employee Count | 68 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -1.80M |
| Effective Tax Rate | 0.08 |
Stock Price Statistics
The stock price has increased by -45.06% in the last 52 weeks. The beta is 1.28, so Lineage Cell Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.28 |
| 52-Week Price Change | -45.06% |
| 50-Day Moving Average | 0.78 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 34.18 |
| Average Volume (20 Days) | 1.57M |
Income Statement
In the last 12 months, Lineage Cell Therapeutics had revenue of $8.95M and earned -$21.49M in profits. Earnings per share was $-0.12.
| Revenue | 8.95M |
| Gross Profit | 8.27M |
| Operating Income | -24.73M |
| Net Income | -21.49M |
| EBITDA | -24.04M |
| EBIT | -24.73M |
| Earnings Per Share (EPS) | -0.12 |
Balance Sheet
The company has $35.44M in cash and $2.95M in debt, giving a net cash position of $32.49M.
| Cash & Cash Equivalents | 35.44M |
| Total Debt | 2.95M |
| Net Cash | 32.49M |
| Retained Earnings | -384.86M |
| Total Assets | 96.59M |
| Working Capital | 20.54M |
Cash Flow
In the last 12 months, operating cash flow was -$28.57M and capital expenditures -$674.00K, giving a free cash flow of -$29.24M.
| Operating Cash Flow | -28.57M |
| Capital Expenditures | -674.00K |
| Free Cash Flow | -29.24M |
| FCF Per Share | -0.17 |
Margins
Gross margin is 92.5%, with operating and profit margins of -276.5% and -240.2%.
| Gross Margin | 92.5% |
| Operating Margin | -276.5% |
| Pretax Margin | -260.28% |
| Profit Margin | -240.2% |
| EBITDA Margin | -268.76% |
| EBIT Margin | -276.5% |
| FCF Margin | -326.89% |
Dividends & Yields
LCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -24% |
| FCF Yield | -26.43% |
Analyst Forecast
The average price target for LCTX is $5, which is 900% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 900% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Oct 31, 1997. It was a forward split with a ratio of 3:1.
| Last Split Date | Oct 31, 1997 |
| Split Type | forward |
| Split Ratio | 3:1 |
Scores
| Altman Z-Score | -3.65 |
| Piotroski F-Score | 2 |